Thanks to visit codestin.com
Credit goes to biopitch.substack.com

BioPitch

BioPitch

Home
Advisory Board
About
Philanthropic drug development: How DEBRA Research is addressing gaps in rare disease drug development
By combining patient advocacy with strategic venture capital, DEBRA Research is de-risking early-stage science to accelerate life-changing therapies for…
 • Yilmaz Biter
How Mallia Innovations is using soluble CD83 to reverse hair loss
Led by biotech veteran Manfred Gröppel and immunologist Prof. Alexander Steinkasserer, Mallia funds its therapeutic development programs through the…
 • Yilmaz Biter
Bridging the gap: Mark Krul’s mission to accelerate the model of oncology drug development
Driven by a mission to bridge the gap between science and patient care, Mark Krul details his strategy for tackling the inefficiencies of oncology drug…
 • Yilmaz Biter
From backpacker to QBiotics Group CEO: harnessing nature to treat cancer
When Stephen Doyle set off on a six-month backpacking trip, he never imagined it would evolve into a global pharmaceutical leadership journey spanning…
 • Yilmaz Biter
Dr. Helmut Schuehsler's journey from the Austrian Alps to building healthcare companies in emerging markets
Dr. Helmut Schuehsler's venture capital career has been instrumental in building Germany’s biotech sector in the 1990s and is now shaping healthcare…
 • Yilmaz Biter

Venture Capital

View all
Philanthropic drug development: How DEBRA Research is addressing gaps in rare disease drug development
By combining patient advocacy with strategic venture capital, DEBRA Research is de-risking early-stage science to accelerate life-changing therapies for…
 • Yilmaz Biter
Bridging the gap: Mark Krul’s mission to accelerate the model of oncology drug development
Driven by a mission to bridge the gap between science and patient care, Mark Krul details his strategy for tackling the inefficiencies of oncology drug…
 • Yilmaz Biter
Dr. Helmut Schuehsler's journey from the Austrian Alps to building healthcare companies in emerging markets
Dr. Helmut Schuehsler's venture capital career has been instrumental in building Germany’s biotech sector in the 1990s and is now shaping healthcare…
 • Yilmaz Biter
The education of a biotech executive: hard-earned lessons from Luc Dochez
Luc Dochez, Managing Partner at Droia Ventures, shares invaluable lessons from his two decades in biotech, emphasizing patient-centricity, grit, and…
 • Yilmaz Biter
The credibility challenge: how Catello Somma broke into venture capital
Catello Somma, Partner at Seroba, tells more about his journey into venture capital.
 • Yilmaz Biter

Company building

View all
How Mallia Innovations is using soluble CD83 to reverse hair loss
Led by biotech veteran Manfred Gröppel and immunologist Prof. Alexander Steinkasserer, Mallia funds its therapeutic development programs through the…
 • Yilmaz Biter
Bridging the gap: Mark Krul’s mission to accelerate the model of oncology drug development
Driven by a mission to bridge the gap between science and patient care, Mark Krul details his strategy for tackling the inefficiencies of oncology drug…
 • Yilmaz Biter
From backpacker to QBiotics Group CEO: harnessing nature to treat cancer
When Stephen Doyle set off on a six-month backpacking trip, he never imagined it would evolve into a global pharmaceutical leadership journey spanning…
 • Yilmaz Biter
AATec Medical: Targeting lung disease with a next-generation inhaled biologic
With a focus on innovation and speed, Rüdiger Jankowsky leads AATec Medical in the development of a next-generation inhaled biologic to combat chronic…
 • Yilmaz Biter
Pivoting from prestige to purpose: Paul Peter Tak’s journey to pursue cures
After leaving a distinguished academic career for the biotech world, Dr. Paul Peter Tak’s story challenges the idea that industry and academia are on…
 • Yilmaz Biter

Recent posts

View all
AATec Medical: Targeting lung disease with a next-generation inhaled biologic
With a focus on innovation and speed, Rüdiger Jankowsky leads AATec Medical in the development of a next-generation inhaled biologic to combat chronic…
 • Yilmaz Biter
Pivoting from prestige to purpose: Paul Peter Tak’s journey to pursue cures
After leaving a distinguished academic career for the biotech world, Dr. Paul Peter Tak’s story challenges the idea that industry and academia are on…
 • Yilmaz Biter
The psychology of building biotech teams: Thomas Winter’s journey through three decades of industry evolution
Thomas Winter, founder of the executive search firm Genius Search, leverages his background in psychology to build leadership teams for Europe's most…
 • Yilmaz Biter
The education of a biotech executive: hard-earned lessons from Luc Dochez
Luc Dochez, Managing Partner at Droia Ventures, shares invaluable lessons from his two decades in biotech, emphasizing patient-centricity, grit, and…
 • Yilmaz Biter
Choice for Women: Reimagining birth control on Eindhoven's innovation ground
In a groundbreaking move for reproductive health, Eindhoven's Choice for Women has unveiled a new, non-hormonal birth control device.
 • Yilmaz Biter
From farm to fermentation: Aisling Foley and the ExCulture team’s vision for changing the way heparin is produced
Aisling Foley, CEO and co-founder of Ex-Culture, is drawing on lessons from her Irish farm upbringing to pioneer a sustainable, animal-free future for…
 • Yilmaz Biter
The credibility challenge: how Catello Somma broke into venture capital
Catello Somma, Partner at Seroba, tells more about his journey into venture capital.
 • Yilmaz Biter
From Amsterdam and Brussels to China: an overview of what is happening in the pharmaceutical industry
Hanneke Later-Nijland, a lawyer and partner at Genome Lawyers, as well as the founder of The Genotype Network, reflects on international developments in…
 • Yilmaz Biter
© 2026 Yilmaz Biter · Privacy ∙ Terms ∙ Collection notice
Codestin Search App Start your SubstackGet the app
Substack is the home for great culture